endpts.com·Apr 20, 2026
Nektar Therapeutics' data from a failed Phase 2b alopecia trial nearly aligned with Wall Street expectations, supporting the company's plans to continue developing its drug, rezpegaldesleukin, for this indication.
The insight for you is that despite a setback in their Phase 2b alopecia trial, Nektar Therapeutics' extension phase data met Wall Street expectations, which could signal potential for future development in this indication. This might be a strategic point to monitor for investment opportunities or partnership considerations, particularly if they pivot or adjust their clinical approach moving forward.